3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
4
Oligodendroglioma
2
Astrocytoma
2
Recurrence
1
Pathologic Processes
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Healthy Adult Participants
1
Disease Attributes
1
Interventions
pembrolizumab
3
napabucasin
3
Bevacizumab
3
entinostat
2
Paclitaxel
2
Ocoxin
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Gemcitabine
2
Fluorouracil
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vorasidenib
1
sipuleucel-T
1
pralsetinib
1
palbociclib
1
luprolide acetate gel depot
1
linifanib
1
lenvatinib
1
interferon gamma-1b
1
ficlatuzumab
1
durvalumab
1
catumaxomab
1
Vaccines
1
VB6-845 fusion protein
1
Taxes
1
Sorafenib
1
Pemetrexed
1
Papillomavirus Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Glandular and Epithelial
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing